Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | PD-L1 and other biomarkers for renal cell carcinoma

Hans Hammers • 22 Oct 2018
ESMO 2018
Gastrointestinal Cancer Liver Cancer Atezolizumab Bevacizumab Ipilimumab Nivolumab

Biomarkers drastically increase response rates to targeted therapies; here, Hans Hammers, MD, PhD, of the University of Texas Southwestern Medical Center, Texas, USA, discusses biomarkers for renal cell carcinoma, speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Hans Hammers

2:03
First-line therapy options in mRCC
Hans Hammers • 13 Feb 2020
1:19
HIF-2 inhibitors in RCC
Hans Hammers • 13 Feb 2020
Optimizing immunotherapy duration
Hans Hammers • 15 Feb 2020
RADVAX: pembrolizumab plus radiotherapy
Hans Hammers • 15 Feb 2020

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals